Baudax Bio, Inc. announced on June 30 that it acquired TeraImmune, Inc.
TeraImmune is a privately held biotechnology company working on cell therapies for autoimmune diseases. Key technical assets of TeraImmune include expansion of human regulatory T cells in vitro and receptors targeting pathological immune cells (T cell/ B cell/ antigen presenting cell).
Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing products for acute care settings. The company has multiple non-opioid therapeutics in clinical development for the treatment of pain conditions and is currently promoting their lead product, ANJESO™, indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Baudax Bio had revenue of $848,000 in the 12 months ending March 31, 2023, down -3.85% year-over-year, according to its financial reports.
The deal adds TeraImmune’s experimental hemophilia A cell therapy, TI-168, to Baudax’s portfolio. Financial terms of the all-stock transfer were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the 81st Biotechnology acquisition of 2023.
